| 1 |
34016221 | Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms. | 2022 Jan 31 |
2 |
| 2 |
34625658 | Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma. | 2022 Feb |
2 |
| 3 |
34731767 | Acridine-O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity. | 2022 Jan 5 |
4 |
| 4 |
34967073 | CN-3 increases TMZ sensitivity and induces ROS-dependent apoptosis and autophagy in TMZ-resistance glioblastoma. | 2022 Mar |
3 |
| 5 |
34969742 | Association of MGMT Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type IDH Glioblastoma. | 2022 Jan |
2 |
| 6 |
34976195 | Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation. | 2022 |
3 |
| 7 |
34982371 | The effect of levetiracetam treatment on survival in patients with glioblastoma: a systematic review and meta-analysis. | 2022 Jan |
4 |
| 8 |
35045869 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. | 2022 Jan 19 |
1 |
| 9 |
35061210 | High-risk pituitary adenomas and strategies for predicting response to treatment. | 2022 Mar |
1 |
| 10 |
35119837 | Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture. | 2022 Feb 18 |
2 |
| 11 |
35122621 | Newly Diagnosed Glioblastoma in Elderly Patients. | 2022 Mar |
1 |
| 12 |
35145081 | Acquired temozolomide resistance in MGMTlow gliomas is associated with regulation of homologous recombination repair by ROCK2. | 2022 Feb 10 |
1 |
| 13 |
35163465 | Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. | 2022 Jan 28 |
5 |
| 14 |
35173295 | Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. | 2022 Feb 16 |
1 |
| 15 |
35180887 | Bisulfite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. | 2022 Feb 18 |
1 |
| 16 |
35187626 | Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. | 2022 Mar |
6 |
| 17 |
35205800 | Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance. | 2022 Feb 18 |
6 |
| 18 |
35258987 | Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. | 2022 May 10 |
4 |
| 19 |
35274103 | XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM-AMPK signaling. | 2022 Jan-Dec |
1 |
| 20 |
35278900 | Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. | 2022 Feb 27 |
5 |
| 21 |
35291535 | Reclassification of Glioblastoma Multiforme According to the 2021 World Health Organization Classification of Central Nervous System Tumors: A Single Institution Report and Practical Significance. | 2022 Feb |
1 |
| 22 |
35365623 | Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. | 2022 Apr 1 |
2 |
| 23 |
35372034 | A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications. | 2022 |
2 |
| 24 |
35379142 | Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond O‑6‑Methylguanine‑DNA Methyltransferase. | 2022 Apr 4 |
2 |
| 25 |
35388070 | Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. | 2022 Apr 6 |
7 |
| 26 |
35402913 | Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. | 2022 Jan-Dec |
3 |
| 27 |
35419607 | Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial. | 2022 Apr 14 |
2 |
| 28 |
35440003 | Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. | 2022 Apr 19 |
1 |
| 29 |
35452002 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. | 2022 Jul 1 |
1 |
| 30 |
35453150 | Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05). | 2022 Apr 23 |
1 |
| 31 |
35474499 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. | 2022 May |
4 |
| 32 |
35490896 | Mannose inhibits proliferation and promotes apoptosis to enhance sensitivity of glioma cells to temozolomide through Wnt/β-catenin signaling pathway. | 2022 Jul |
5 |
| 33 |
35491627 | Dual Temozolomide and ICI Treatment Is Efficacious and Safe in MSS mCRC. | 2022 May 2 |
1 |
| 34 |
35511454 | Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter. | 2022 May 2 |
1 |
| 35 |
35511800 | Retraction: Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase. | 2022 |
1 |
| 36 |
35522273 | Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. | 2022 May 6 |
1 |
| 37 |
35559231 | Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases. | 2022 |
3 |
| 38 |
35563629 | Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. | 2022 May 7 |
7 |
| 39 |
35565362 | Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. | 2022 Apr 29 |
2 |
| 40 |
35566308 | Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC. | 2022 May 5 |
2 |
| 41 |
35625018 | Elderly Gliobastoma Patients: The Impact of Surgery and Adjuvant Treatments on Survival: A Single Institution Experience. | 2022 May 11 |
1 |
| 42 |
32589560 | Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. | 2021 |
1 |
| 43 |
32644826 | Pulsed and Discontinuous Electromagnetic Field Exposure Decreases Temozolomide Resistance in Glioblastoma by Modulating the Expression of O6-Methylguanine-DNA Methyltransferase, Cyclin-D1, and p53. | 2021 Sep |
3 |
| 44 |
32710211 | MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. | 2021 Mar |
7 |
| 45 |
32813021 | TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. | 2021 Mar 25 |
4 |
| 46 |
32813186 | Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. | 2021 Jan |
1 |
| 47 |
33037945 | Optimal treatment strategy for adult patients with newly diagnosed glioblastoma: a systematic review and network meta-analysis. | 2021 Aug |
3 |
| 48 |
33040565 | Narrative review of palliative hypofractionated radiotherapy for high grade glioma. | 2021 Jan |
4 |
| 49 |
33049091 | Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond. | 2021 Jan |
1 |
| 50 |
33085768 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. | 2021 Mar 25 |
1 |